- Trial phase
- Preclinical / Discovery
- Time to market
- Unknown, likely 5+ years if it advances through preclinical development, IND-enabling studies, and clinical trials. The drug is not yet in clinical trials.
- Why 1/10
- No hard dated catalyst is scheduled for ARGX-109 in the next ~12 months. The drug is preclinical/early-discovery with no IND filing, no clinical trial registrations, and no disclosed development timeline. As a minor early-stage program within a large-cap biotech ($874/share, ~$50B+ market cap) driven by its approved VYVGART franchise, even positive preclinical data would have negligible impact on the stock.
ARGX-109 is a preclinical/early-discovery pipeline asset at argenx, a company overwhelmingly driven by its approved VYVGART franchise ($1.7B quarterly sales). This drug is too early-stage to move the stock independently. Investors should focus on argenx's near-term catalysts: Phase 3 empasiprubart MMN data (December 2026), the IMNM sBLA submission (year-end 2026), and the pediatric gMG PDUFA (February 2027).
Price Chart
Executive Summary
ARGX-109 is an early-stage/preclinical pipeline drug candidate from argenx SE (Nasdaq: ARGX), a large-cap biotech company best known for its approved FcRn-blocking antibody VYVGART (efgartigimod). ARGX-109 was listed among argenx's pipeline assets in the company's Q3 2026 earnings filing, but its specific mechanism, molecular target, and development stage have not been publicly disclosed. No clinical trial registrations exist for ARGX-109 on ClinicalTrials.gov, indicating it remains in preclinical or very early discovery research. As a minor early-stage program within a company generating $1.7B in quarterly VYVGART sales with a ~$50B+ market cap, ARGX-109 has no near-term catalysts and is not a meaningful standalone driver for the stock.
How It Works
ARGX-109 is an early-stage investigational antibody drug candidate being developed by argenx. Its specific molecular target and mechanism of action have not been publicly disclosed. argenx specializes in antibody-based therapies that modulate the immune system, particularly FcRn antagonists (like their approved drug VYVGART), but ARGX-109's target is unknown from available public information.
Trial Status
ARGX-109 is in preclinical or early discovery research. No clinical trials have been initiated or registered on ClinicalTrials.gov. The drug was listed among argenx's pipeline candidates in the Q3 2026 earnings filing but no specific development details were disclosed.
The Two-Sided Case
Upcoming Catalysts
- No scheduled catalysts for ARGX-109 specifically. For argenx overall: Phase 3 empasiprubart MMN topline data (December 2026), IMNM sBLA submission (year-end 2026), pediatric gMG PDUFA (February 2027).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ARGENX SE 6-K ARGX ·Originating report